Reviewing Ligand Pharmaceuticals (NASDAQ:LGND) & WAVE Life Sciences (NASDAQ:WVE)

Ligand Pharmaceuticals (NASDAQ:LGND – Get Free Report) and WAVE Life Sciences (NASDAQ:WVE – Get Free Report) are both healthcare companies, but which is the better stock? We will compare the two businesses based on the strength of their profitability, earnings, dividends, risk, valuation, institutional ownership and analyst recommendations.

Profitability

This table compares Ligand Pharmaceuticals and WAVE Life Sciences’ net margins, return on equity and return on assets.

Net Margins Return on Equity Return on Assets
Ligand Pharmaceuticals 20.27% 5.22% 2.74%
WAVE Life Sciences -296.86% -44.66% -36.80%

Institutional and Insider Ownership

91.3% of Ligand Pharmaceuticals shares are owned by institutional investors. Comparatively, 89.7% of WAVE Life Sciences shares are owned by institutional investors. 5.6% of Ligand Pharmaceuticals shares are owned by insiders. Comparatively, 24.3% of WAVE Life Sciences shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock is poised for long-term growth.

Analyst Recommendations

This is a breakdown of current ratings and price targets for Ligand Pharmaceuticals and WAVE Life Sciences, as provided by MarketBeat.com.

Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Ligand Pharmaceuticals 0 1 8 0 2.89
WAVE Life Sciences 1 2 15 2 2.90

Ligand Pharmaceuticals presently has a consensus price target of $355.38, indicating a potential upside of 17.79%. WAVE Life Sciences has a consensus price target of $20.44, indicating a potential upside of 612.35%. Given WAVE Life Sciences’ stronger consensus rating and higher probable upside, analysts clearly believe WAVE Life Sciences is more favorable than Ligand Pharmaceuticals.

Earnings and Valuation

This table compares Ligand Pharmaceuticals and WAVE Life Sciences”s top-line revenue, earnings per share and valuation.

Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio
Ligand Pharmaceuticals $268.09 million 22.51 $124.45 million $2.24 134.69
WAVE Life Sciences $70.92 million 7.98 -$204.38 million ($1.07) -2.68

Ligand Pharmaceuticals has higher revenue and earnings than WAVE Life Sciences. WAVE Life Sciences is trading at a lower price-to-earnings ratio than Ligand Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Risk and Volatility

Ligand Pharmaceuticals has a beta of 1.16, suggesting that its stock price is 16% more volatile than the S&P 500. Comparatively, WAVE Life Sciences has a beta of -1.4, suggesting that its stock price is 240% less volatile than the S&P 500.

Summary

Ligand Pharmaceuticals beats WAVE Life Sciences on 10 of the 15 factors compared between the two stocks.

About Ligand Pharmaceuticals

(Get Free Report)

Ligand Pharmaceuticals is a biopharmaceutical company that works with pharmaceutical and biotechnology partners to develop and commercialize medicines. Rather than focusing primarily on selling drugs directly, Ligand licenses technologies and drug-development assets and may receive royalties and other payments from partner programs. Its technologies include Captisol, a formulation platform designed to improve the solubility and delivery of certain medicines. Ligand also holds economic interests in a portfolio of partnered products and drug candidates across multiple therapeutic areas.

About WAVE Life Sciences

(Get Free Report)

WAVE Life Sciences Ltd. is a biotechnology company developing RNA-based medicines for genetically defined diseases. Founded in 2012, the company is headquartered in Cambridge, Massachusetts, and uses its oligonucleotide chemistry and drug-design capabilities to develop treatments intended to alter or regulate gene expression. Its research includes antisense oligonucleotide therapies and RNA-editing approaches. Programs have targeted conditions such as Huntington’s disease and alpha-1 antitrypsin deficiency, with the latter exploring RNA editing to address a disease-causing genetic variant.

Receive News & Ratings for Ligand Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Ligand Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.